Viking Therapeutics (VKTX) Competitors

Genmab A/S (NASDAQ:GMAB) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

Do insiders & institutionals have more ownership in GMAB or VKTX?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts prefer GMAB or VKTX?

Genmab A/S presently has a consensus target price of $45.20, suggesting a potential upside of 117.31%. Viking Therapeutics has a consensus target price of $106.75, suggesting a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Viking Therapeutics	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.15

Does the MarketBeat Community favor GMAB or VKTX?

Viking Therapeutics received 460 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Viking Therapeutics	Outperform Votes 621 79.92%	Underperform Votes 156 20.08%

Is GMAB or VKTX more profitable?

Genmab A/S has a net margin of 23.49% compared to Viking Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.64% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Viking Therapeutics	N/A	-12.73%	-12.31%

Which has stronger valuation & earnings, GMAB or VKTX?

Genmab A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	5.76	$631.91M	$1.03	20.19
Viking Therapeutics	N/A	N/A	-$85.89M	-$0.93	-35.11

Which has more risk & volatility, GMAB or VKTX?

Genmab A/S has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Does the media prefer GMAB or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Viking Therapeutics and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.87 beat Viking Therapeutics' score of 0.44 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S and Viking Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.